After approval of first cannabis-based drug in USA, what’s next?

Analysis from HempToday, the voice of the global hemp industries.

Recent approval of GW Pharmaceutical’s cannabidiol-based drug Epidiolex in the United States not only will soon give patients needed relief, but can spur further research into cannabinoids as well as expansion of the CBD sector overall. That could set off a cycle that would result in a greater number of treatment options for patients, GW has said.

You need to login to view the rest of the content. Please . Not a Member? Join Us